Janus Henderson Group PLC Takes Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Janus Henderson Group PLC bought a new position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,067,196 shares of the company's stock, valued at approximately $24,994,000. Janus Henderson Group PLC owned about 2.11% of Tyra Biosciences as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. Perceptive Advisors LLC grew its holdings in Tyra Biosciences by 50.5% in the second quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company's stock worth $16,108,000 after purchasing an additional 338,208 shares during the period. Ally Bridge Group NY LLC acquired a new position in shares of Tyra Biosciences during the second quarter valued at about $4,232,000. Ensign Peak Advisors Inc acquired a new position in shares of Tyra Biosciences during the second quarter valued at about $3,047,000. American Century Companies Inc. grew its holdings in shares of Tyra Biosciences by 582.9% during the second quarter. American Century Companies Inc. now owns 170,283 shares of the company's stock valued at $2,723,000 after buying an additional 145,346 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Tyra Biosciences by 18.6% during the first quarter. Vanguard Group Inc. now owns 899,800 shares of the company's stock valued at $14,757,000 after buying an additional 140,833 shares during the last quarter. Institutional investors own 84.14% of the company's stock.

Insiders Place Their Bets

In other news, CFO Alan Fuhrman acquired 9,500 shares of the business's stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average cost of $16.00 per share, with a total value of $152,000.00. Following the transaction, the chief financial officer now owns 12,849 shares of the company's stock, valued at $205,584. This trade represents a 283.67 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Todd Harris sold 10,092 shares of the stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $24.13, for a total transaction of $243,519.96. Following the sale, the chief executive officer now directly owns 1,479,528 shares in the company, valued at $35,701,010.64. This trade represents a 0.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 101,050 shares of company stock worth $2,235,492. 15.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

TYRA has been the topic of a number of recent analyst reports. Wedbush reissued an "outperform" rating and set a $28.00 price target on shares of Tyra Biosciences in a research report on Friday, October 25th. Piper Sandler initiated coverage on shares of Tyra Biosciences in a research report on Thursday, August 15th. They issued an "overweight" rating and a $33.00 price target on the stock. Oppenheimer boosted their price objective on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an "outperform" rating in a research note on Thursday, September 19th. HC Wainwright reduced their price objective on shares of Tyra Biosciences from $32.00 to $30.00 and set a "buy" rating for the company in a research note on Monday, November 11th. Finally, Bank of America raised shares of Tyra Biosciences from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $22.00 to $31.00 in a research note on Friday, October 18th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $31.00.

Tyra Biosciences Stock Performance

NASDAQ:TYRA traded up $0.56 during midday trading on Friday, reaching $15.73. 600,165 shares of the stock traded hands, compared to its average volume of 230,945. The company has a fifty day moving average of $19.30 and a 200 day moving average of $19.71. Tyra Biosciences, Inc. has a 12 month low of $11.24 and a 12 month high of $29.60. The stock has a market capitalization of $795.94 million, a P/E ratio of -9.77 and a beta of 1.01.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.01). On average, analysts predict that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.